PsychoGenics is a Preclinical CRO with expertise in the CNS and orphan disorders. We are known for our cutting edge translational approach to research, our customized solutions, the breadth and quality of our work, as well as for our ability to identify statistically relevant phenotypic changes that help our clients quantify the efficacy of their treatments before they move into the clinic. The Company?s capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis. Complementing its extensive capabilities, PsychoGenics offers a variety of validated mouse models including in-licensed transgenic models that support research in areas such as Alzheimer?s disease, Huntington?s disease, Parkinson?s disease, Autism spectrum disorders, psychosis/schizophrenia, Spinal Muscular Atrophy (SMA), muscular dystrophy and other muscle disorders. Mission:?Our mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next generation of treatments for CNS and orphan disorders and reduce the attrition rate in clinical development.
51 to 200Type
Company - PrivateRevenue
$10 to $25 million (USD) per yearIndustry
Biotech & PharmaceuticalsCompetitors